checkAd

     1310  0 Kommentare Theravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva - Seite 4

    Contact Information:

    Renee Gala
    Chief Financial Officer
    650-808-4045
    investor.relations@theravance.com

    Tim Brons
    Vida Strategic Partners (media)
    646-319-8981
    tbrons@vidasp.com

    Lesen Sie auch


    Seite 4 von 4

    Verfasst von Marketwired
    3 im Artikel enthaltene WerteIm Artikel enthaltene Werte
    Theravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva - Seite 4 DUBLIN, IRELAND--(Marketwired - Jun 20, 2016) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva) have disclosed positive top-line results from the …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer